Pharmaceuticals & Biotech Swiss Community

Catalysts Preliminary Unaudited Revenue and Cash Revenue: €266.8 million, representing a year-on-year increase of 188% compared to €92.8 million in 2023. This includes significant project-based revenues from GI Genius™ and Winlevi® of €190.2 million.

Valuation ### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der Ergebnisse Roche hat für das Jahr 2024 ein solides Wachstum von 7 % auf 60,5 Mrd. CHF erzielt, was die Erwartungen leicht übertroffen hat.

211011 Draupnir noch ein Anteil von rund 55,5% an Polypeptide. Der «Free Float» an der Börse SIX erhöht sich dadurch gleichzeitig von 40,0 auf rund 44,5%.

Key Takeaways Strong cash position and no debt provide flexibility for strategic investments, boosting future profitability and earnings. Focus on AI-driven applications and digital transformation bolsters market reach, revenue opportunities, and long-term efficiency.

Key Takeaways Expansion into South Korea and FDA approval in Malaysia bolster Tecan's production and revenue growth potential in medical devices. Innovations in genomics and proteomics could drive demand and revenue as new technologies gain market traction.

Key Takeaways Novartis shows strong growth in key brands and anticipates continued pipeline success, potentially boosting future sales and earnings. Expanding innovative therapies and operational efficiencies are expected to offset patent expirations and support net margin expansion.

Key Takeaways The EVOLVE+ strategy and strategic M&A activities are set to enhance growth, expand services, and improve margins for Siegfried Holding. Investments in new technologies and diversification across portfolios are expected to drive revenue stability and efficiency improvements.

Key Takeaways Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides. Strategic investments and innovations in API production and U.S. market expansion are expected to sustain revenue growth and optimize margins in expanding pharmaceutical sectors.

Key Takeaways Focus on CDMO business and Vacaville acquisition to drive revenue growth and boost sales. Strategic CHI exit and investment in growth to enhance margins and earnings.